89,007 Shares in Amneal Pharmaceuticals, Inc. $AMRX Bought by HighTower Advisors LLC

HighTower Advisors LLC purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 89,007 shares of the company’s stock, valued at approximately $1,121,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Abacus Wealth Partners LLC purchased a new stake in Amneal Pharmaceuticals in the fourth quarter worth $288,000. Convergence Investment Partners LLC grew its stake in Amneal Pharmaceuticals by 51.1% in the fourth quarter. Convergence Investment Partners LLC now owns 146,430 shares of the company’s stock worth $1,845,000 after purchasing an additional 49,513 shares during the period. Swiss Life Asset Management Ltd purchased a new stake in Amneal Pharmaceuticals in the fourth quarter worth $254,000. Truist Financial Corp grew its stake in Amneal Pharmaceuticals by 87.4% in the fourth quarter. Truist Financial Corp now owns 25,608 shares of the company’s stock worth $323,000 after purchasing an additional 11,944 shares during the period. Finally, Strs Ohio purchased a new stake in Amneal Pharmaceuticals in the fourth quarter worth $52,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Weiss Ratings cut Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Truist Financial upped their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Barclays upped their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Finally, UBS Group began coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 target price on the stock. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.17.

Amneal Pharmaceuticals Trading Up 5.0%

Amneal Pharmaceuticals stock opened at $13.52 on Friday. The business’s fifty day simple moving average is $12.70 and its two-hundred day simple moving average is $12.96. Amneal Pharmaceuticals, Inc. has a 12 month low of $7.07 and a 12 month high of $15.42. The company has a market capitalization of $4.31 billion, a price-to-earnings ratio of 35.58 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The business had revenue of $722.52 million for the quarter. On average, equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the sale, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.